2-chloro-5,6,7-trimethoxy-1H-quinazolin-4-one | 827605-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-5,6,7-trimethoxy-1H-quinazolin-4-one
• 英文别名: 2-Chloro-5,6,7-trimethoxyquinazolin-4(1H)-one；2-chloro-5,6,7-trimethoxy-3H-quinazolin-4-one
• CAS: 827605-47-0
• 化学式: C₁₁H₁₁ClN₂O₄
• 分子量: 270.672
• InChiKey: GKPRWIVTCJUQHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  69.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  {3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzyl}-methyl-amine 、 2-chloro-5,6,7-trimethoxy-1H-quinazolin-4-one 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 以82.12%的产率得到2-({3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzyl}-methyl-amino)-5,6,7-trimethoxy-1H-quinazolin-4-one
  参考文献：
  名称：

  [EN] ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS
  [FR] COMPOSES DE QUINAZOLINONE SUBSTITUES PAR ARYLAMINE

  摘要：

  公开号：

  WO2005005395A3

文献信息

• [EN] 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINONE SUBSTITUÉS EN POSITION 5
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005005397A1

  公开（公告）日：2005-01-20

  Compounds which are alpha- 1A/B adrenoceptor antagonists and which are represented by Formula (I), wherein Q is a monocyclic or bicyclic optionally-substituted heterocyclic ring as defined in the Specification; Z is -C(=O)- or-S(=O)2-; R and R' are lower alkyl; R5 is halogen, cyano, hydroxy, -R6, or -OR6; and R6 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclo, or substituted heterocyclo; and pharmaceutically- acceptable salts, hydrates, prodrugs, and isomers thereof.

  具有α-1A/B肾上腺素受体拮抗作用的化合物，其由式（I）表示，其中Q是根据说明书中定义的单环或双环可选择取代的杂环环；Z是-C（=O）-或-S（=O）2-；R和R'是较低的烷基；R5是卤素、氰基、羟基、-R6或-OR6；而R6是烷基、取代烷基、芳基、取代芳基、杂芳基、取代杂芳基、环烷基、取代环烷基、杂环烷基或取代杂环烷基；以及其药用盐、水合物、前药和异构体。
• 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
  申请人：Chin Elbert

  公开号：US20050124607A1

  公开（公告）日：2005-06-09

  Compounds which are alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Q is a monocyclic or bicyclic optionally-substituted heterocyclic ring as defined herein; Z is —C(═O)— or —S(═O) 2 —; R and R′ are lower alkyl; R 5 is halogen, cyano, hydroxy, —R 6 , or —OR 6 ; and R 6 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclo, or substituted heterocyclo; and pharmaceutically-acceptable salts, hydrates, prodrugs, and isomers thereof.

  本发明涉及一种α-1A/B肾上腺素受体拮抗剂，其化合物由式I表示：其中Q是单环或双环的、可选取代的杂环，如定义所述；Z是—C(═O)—或—S(═O)2—；R和R′是低碳基；R5是卤素、氰基、羟基、—R6或—OR6；R6是烷基、取代烷基、芳基、取代芳基、杂芳基、取代杂芳基、环烷基、取代环烷基、杂环基或取代杂环基；以及其药学上可接受的盐、水合物、前药和同分异构体。
• Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
  申请人：Connolly Joseph Terrence

  公开号：US20050038016A1

  公开（公告）日：2005-02-17

  Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.

  公式I所代表的化合物，可用作α-1A/B肾上腺素受体拮抗剂，用于治疗与α-1A/B肾上腺素受体活性相关的疾病的方法，以及制备所述化合物的方法，其中Ar、Z、R、R′、R5和R10如本文所定义。
• 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1644343A1

  公开（公告）日：2006-04-12
• ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1644369A2

  公开（公告）日：2006-04-12